RM-131

Phase 2Small molecule

MMotus Therapeutics, Inc.

RM-131 is one of 101 small molecule programs targeting Gastroparesis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroparesisActive, not recruiting

Anorexia NervosaActive, not recruiting

Chronic ConstipationActive, not recruiting

GastroparesisPhase 2

Active, not recruiting

Anorexia NervosaPhase 2

Active, not recruiting

Chronic ConstipationPhase 1

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Gastroparesis

#DrugCompanyPhaseTrials

Haldol

DDePuy Orthopaedics

Approved

1 2

Zelnorm

AAlfasigma S.p.A.

Approved

1 3

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 4

Relistor

Pitocin

Kytril

CConrado Roberto Hoffmann Filho

Approved

—7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Resotran

2 9

Mosapride

SSeoul National University Hospital

Approved

1 10

Reglan

IIstituto Clinico Humanitas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic constipation3 trials

Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

Completed·MMotus Therapeutics, Inc.·Phase 2·NCT01781104·48 enrolled

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation

Terminated·MMotus Therapeutics, Inc.·Phase 2·NCT01955616·18 enrolled

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

Completed·MMotus Therapeutics, Inc.·Phase 1·NCT02137642·18 enrolled

Gastroparesis2 trials

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Completed·MMotus Therapeutics, Inc.·Phase 2·NCT01571297·204 enrolled

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

Completed·MMotus Therapeutics, Inc.·Phase 1·NCT01394055·20 enrolled

Anorexia Nervosa1 trial

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

Completed·MMotus Therapeutics, Inc.·Phase 2·NCT01642550·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for RM-131. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RM-131 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RM-131. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Motus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMotus Therapeutics, Inc.

RM-131

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic constipation3 trials

Gastroparesis2 trials

Anorexia Nervosa1 trial

References

Drug Info

Quick Facts

Related News